Clinical Trial

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-07; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Recruiting 2024-02-26
Trial Details
NCT Number NCT05905887
Lead Sponsor Asan Medical Center
Conditions Gastrointestinal Stromal Tumors
Enrollment 48 participants
Start Date 2023-09-06
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-07